London, UK – 29 September 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: Oxford Biomedica), a leading gene and cell therapy group, announces, in accordance with Listing Rule 9.6.18, that all resolutions proposed at its General Meeting, held today in London, were duly passed.
The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Group’s website at www.oxfordbiomedica.co.uk (located on pages 153 to 155 of the prospectus dated 13 September 2016).
Certified copies of the document setting out the above resolutions passed at this General Meeting have been submitted to the National Storage Mechanism and will shortly be available for inspection at: https://www.morningstar.co.uk/uk/NSM.
The results of the proxy voting in advance of the meeting are shown below. On the 12 September 2016) there were 2,703,806,022 1 pence ordinary shares in issue, each carrying one vote per share.
| Resolution |
Votes For |
Votes at Chairman’s Discretion |
Votes atother proxy |
Votes |
Votes |
Total |
Result |
|---|---|---|---|---|---|---|---|
|
Ordinary resolutions |
|||||||
| 1 |
1,387,198,975 |
448,954 | 5,504,000 | 8,776,212 | 2,825,351 | 1,401,928,141 | Passed |
| 2 |
1,387,621,067 |
449,989 | 5,504,000 | 8,299,192 | 2,879,244 | 1,401,874,248 | Passed |
|
Special resolution |
|||||||
| 3 |
1,387,150,807 |
584,793 | 5,504,000 | 8,634,618 | 2,879,274 | 1,401,874,218 | Passed |
|
Ordinary resolution |
|||||||
| 4 |
911,439,072 |
466,032 | 5,504,000 | 8,508,723 | 478,835,665 | 925,917,827 | Passed |
In addition, following the proposed fundraising announced on 13 September 2016, the table below details the number of Ordinary Shares now beneficially held by the Directors and their connected persons in the share capital of the Company:
| Name of Director |
Title | Number of Ordinary Shares Purchased |
Number of Ordinary Shares beneficially held immediately following Admission |
Percentage of issued ordinary shares beneficially held immediately following Admission |
|---|---|---|---|---|
| Lorenzo Tallarigo | Non-executive Chairman | 1,000,000 | 1,354,847 | 0.04% |
| John Dawson | Chief Executive Officer | 666,666 | 3,925,685 | 0.13% |
| Tim Watts | Chief Financial Officer | 1,000,000 | 7,395,124 | 0.24% |
| Peter Nolan | Chief Business Officer | 266,666 | 1,668,634 | 0.05% |
| Andrew Heath | Non-executive Director | 200,000 | 1,500,000 | 0.05% |
| Martin Diggle(1) | Non-executive Director | 100,000,000 | 575,850,000 | 18.65% |
| Stuart Henderson | Non-executive Director | 333,333 | 333,833 | 0.01% |
(1) Includes interests of Vulpes Life Sciences Fund and Vulpes Testudo Fund and the Related Party Subscription
Application has been made by the Company to the UK Listing Authority and the London Stock Exchange for 383,371,665 Ordinary Shares of 1 pence each in the Company to be admitted to the premium listing segment of the Official List of the UK Listing Authority and to be traded on the main market of the London Stock Exchange. The shares will be issued fully paid and will rank pari passu in all respects with the existing issued Ordinary Shares of 1 pence each in the Company. It is expected that admission of the shares will become effective at 8.00 a.m. on 4 October 2016, and that dealings will commence at that time.
– Ends –